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Abstract
Background: Uveal melanoma (UM) is a rare eye tumor. There are two classes of UM, which can be discriminated
by the chromosome 3 status or global mRNA expression profile. Metastatic progression is predominantly originated
from class II tumors or from tumors showing loss of an entire chromosome 3 (monosomy 3). We performed
detailed EFS (embryonal Fyn-associated substrate) methylation analyses in UM, cultured uveal melanocytes and
normal tissues, to explore the role of the differentially methylated EFS promoter region CpG island in tumor
classification and metastatic progression.
Methods: EFS methylation was determined by direct sequencing of PCR products from bisulfite-treated DNA or by
sequence analysis of individual cloned PCR products. The results were associated with clinical features of tumors
and tumor-related death of patients.
Results: Analysis of 16 UM showed full methylation of the EFS CpG island in 8 (50%), no methylation in 5 (31%)
and partial methylation in 3 (19%) tumors. Kaplan-Meier analysis revealed a higher risk of metastatic progression for
tumors with EFS methylation (p = 0.02). This correlation was confirmed in an independent set of 24 randomly
chosen tumors. Notably, only UM with EFS methylation gave rise to metastases. Real-time quantitative RT-PCR
expression analysis revealed a significant inverse correlation of EFS mRNA expression with EFS methylation in UM.
We further found that EFS methylation is tissue-specific with full methylation in peripheral blood cells, and no
methylation in sperm, cultured primary fibroblasts and fetal muscle, kidney and brain. Adult brain samples, cultured
melanocytes from the uveal tract, fetal liver and 3 of 4 buccal swab samples showed partial methylation. EFS
methylation always affects both alleles in normal and tumor samples.
Conclusions: Biallelic EFS methylation is likely to be the result of a site-directed methylation mechanism. Based on
partial methylation as observed in cultured melanocytes we hypothesize that there might be methylated and
unmethylated precursor cells located in the uveal tract. The EFS methylation of a UM may depend on which type
of precursor cell the tumor originated from.
Background
UM is the most frequent primary intraocular tumor in
adults. Two classes of UM have been defined that differ
in chromosome 3 status, metastatic risk and global
mRNA expression profiles [1,2]. As tumors with monos-
omy 3 are tightly associated with metastatic progression,
chromosome 3 testing is used to predict patients’ prog-
nosis [3,4]. Recently, inactivating somatic mutations in
the gene encoding BRCA1-associated protein 1 (BAP1)
on chromosome 3p21.1 were found to be frequent only
in those UM that showed expression profiles linked to
high metastatic potential [5]. One possible explanation
for the clinical and genetic dichotomy of UM is distinct
cell lineage, meaning that the two tumor classes stem
from different melanocytic precursor cells located in the
uveal tract [2,6]. In this regard, many examples are
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cells are characterized by distinct epigenetic patterns [7].
Most epigenetic studies in cancer focus on altered
methylation of CpG islands (CGIs), which are found in
the promoter regions of about 60% of all genes. With
the exception of imprinted genes, genes on the inactive
X-chromosome in females, germline-specific genes as
well as a few developmental genes, the cytosine residues
within CGIs > 500 bp are mostly unmethylated [8,9]. It
is commonly assumed that epimutations, like other
genetic changes in cancer, develop in a random manner
and are then selected for growth advantage to the
mutant cell clone. For example, hypermethylation of
promoter-associated CGIs can result in transcriptional
silencing of tumor suppressor genes (TSG) [10]. In
these instances - in line with the model of two hit inac-
tivation - one mutational hit alters the methylation pat-
tern of one allele and the second allele is either lost or
inactivated by a structuralm u t a t i o n .H o w e v e r ,C G I
methylation is not necessarily the result of an epimuta-
tion. In recent years, an increasing number of non-
imprinted, autosomal CGIs and CpG-rich regions have
been identified that are already methylated in non-neo-
plastic cells [8,9,11]. In some regions, this kind of CpG
methylation establishes long-term gene inactivation and
is part of the process of cell differentiation from pluri-
potent embryonic stem cells to terminally differentiated
somatic cells [12-14]. This process finally results in a
cell type specific methylation pattern [7]. A potential
link between cell differentiation and cancer is suggested
by the observation that genes that are preferentially
hypermethylated in cancer are often marked for tran-
scriptional repression through association with poly-
comb group proteins in embryonic stem cells [15,16].
Several methylation studies have been conducted to
identify genes that, if hypermethylated, contribute to
initiation and progression of UM [17-20]. Recently, we
performed a comprehensive search for hypermethylation
events in 16 UM using a screening assay based on
methylation-sensitive restriction digest of genomic DNA
followed by PCR amplification and array based detection
of 323 different CGIs. Preliminary results of this screen-
ing revealed a CGI located in the promoter region of
the EFS gene with a methylation pattern that is very
unusual for TSGs. This prompted us to perform a
detailed methylation analysis on the EFS CGI in UM
and normal tissues.
Methods
Patients and specimens
Fresh tumor and peripheral blood samples were
obtained from patients with UM treated at the Ophthal-
mology Department of the University Hospital of Essen
by primary enucleation without prior radiation or
chemotherapy. All patients were given diagnoses accord-
ing to current ophthalmologic criteria. Follow-up data
including tumor-related cause of death are available
from all patients. All tumors analyzed in this study were
selected from a cohort of 262 tumors with either
m o n o s o m y3o rd i s o m y3 .T h es e to f1 6t u m o r s( s e tI )
used to screen for and confirm altered methylation in
UM was selected to equally represent tumors with
monosomy 3 and disomy 3. The chromosome 3 status
of all tumors was determined by microsatellite analysis
[21]. The second set of 24 tumors (set II) was randomly
chosen from the same cohort of 262 tumors, excluding
tumor set I. Tumor and blood samples were stored at
-80°C and -20°C, respectively. DNA from peripheral
blood cells of patients and normal controls was
extracted using the EZ1 DNA Blood 350 μlK i t( Q i a -
gen). RNA and DNA purification from primary tumors
was performed as described elsewhere [2]. Uveal mela-
nocytes were isolated from eyes that were obtained from
anonymous individuals not diagnosed with UM and
were cultured in medium containing G418 at concentra-
tions toxic for non-melanocytic cells [22]. Primary skin
fibroblasts were obtained from healthy donors and culti-
vated as described elsewhere [23]. DNA from fibroblasts
and buccal swabs of healthy donors was extracted using
the EZ1 DNA Tissue Kit (Qiagen). DNA material from
various human tissues was provided by Ralf Hermann
(fetal brain), Dirk Prawitt (fetal liver, kidney and mus-
cle), Bernhard Zabel (adult brain) and Osman El-Maarri
(sperm). The research followed the tenets of the
Declaration of Helsinki and was approved by the institu-
tional ethical committee. Informed consent was obtained
from the tumor patients after detailed explanation of the
nature and possible consequences of the study.
Methylation analysis
Bisulfite modification of DNA was performed using an
established protocol with minor modifications [24].
Genomic DNA (1-2 μgi n5 0μl) was denatured for 15
min at 37°C by adding 5.5 μlo f3MN a O H .F o rc o m -
plete denaturation, samples w e r ei n c u b a t e da t9 5 ° Cf o r
2 min and immediately cooled on ice. The bisulfite solu-
tion was freshly prepared by dissolving 4.25 g of sodium
bisulfite (Sigma) in 7.5 ml H2O. 450 μl of 50 mM hydro-
chinone solution was added and the pH was adjusted to
5.15 by adding 0.5 ml of 10 M NaOH. The denatured
DNA solution was mixed with 500 μl of the bisulfite
solution and incubated at 50°C for 16-20 h in the dark.
The DNA was recovered using the Wizard DNA Clean-
Up System (Promega) followed by elution in 50 μlp r e -
warmed H2O (65°C). Subsequently, 5.5 μl of 3 M NaOH
was added and the samples were incubated for 15 min
at 37°C. The solution was then neutralized by adding 55
μlo f6MN H 4OAc pH 7.0. The DNA was ethanol
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pended in 15-30 μl of water depending on initial DNA
input. To analyze the regions of interest, PCR was per-
formed in a total volume of 25 μl containing 3 μlo f
bisulfite treated DNA, 0.2 mM of each dNTP, 0.2 μMo f
each primer, 2.5 μl 10x PCR-Puffer, 2.5 mM MgCl2 and
1.5 U Taq Polymerase (AmpliTaq Gold, Applied Biosys-
tems, Foster City, CA) using a GeneAmp 9700 system.
A touch down protocol was adopted as follows [25]:
After denaturation at 95°C for 5 min, the annealing tem-
perature was decreased 0.5°C every cycle from 63°C to
56°C, at which temperature 35 cycles were carried out.
For all cycles, annealing was performed for 1 min, dena-
turation at 95°C for 20 sec and extension at 72°C for 1
min, followed by a final extension at 72°C for 5 min. To
facilitate direct sequence analysis of PCR products from
bisulfite-treated templates, GC-tagged primers were
used containing additional nucleotides at the 5’ end
(indicated by bold letters) that do not bind to the tem-
plate. The tags contain C and G nucleotides which are
required for internal normalization during the Sanger
sequencing [26]. Primer sequences: EFSfw:
CTTGCTTCCTGGCACGAGTTTYGTTTTGGTTTT
GTTTTAG; EFSrev: TGTAAAACGACGGCCAGTCA-
TATTATCACTAAAACCAAAATCC. After agarose gel
electrophoresis and purification using MinElute™ Gel
Extraction Kit (Qiagen), sequence analysis was per-
formed on an ABI 3100 automated capillary genetic
analyzer (ABI) using Big Dye 1.1 (ABI) using a primer
complementary to the tag sequence. EFS methylation
was determined on the basis of all evaluable CpG posi-
tions in the analyzed region (11 CpGs located in the
region chr14: 23835859-23835970 (GRCh37/hg19)). The
analyzed region was classified as showing (i) full methy-
lation if the T signal was absent or very low at every
CpG position, (ii) no methylation in the absence of a C
signal at every CpG position and (iii) partial methylation
if both signals were present at some or all CpG posi-
tions (Figure 1). For sequence analysis of individual
alleles, selected PCR products were cloned into the
pGEM-T easy vector (Promega), according to manufac-
turer’s instructions. This vector provides ready-to-use
T-overhangs for ligation with A-overhangs of PCR-pro-
ducts. We cloned the same PCR products that had been
analyzed by direct sequencing before and chose samples
that showed partial methylation and that were informa-
tive for a SNP in the analyzed region (rs3759609). We
picked 15-20 colonies per sample from which we iso-
lated plasmid DNA using the Plasmid Mini Kit (Qiagen).
The cloned fragments were sequenced using the SP6
Promoter Primer (Promega, Cat.# Q5011) and aligned
with the help of the BDPC web interface http://bio-
chem.jacobs-university.de/BDPC/) [27]. Sequences from
cloned EFS PCR products were analyzed in their full
lengths (28 CpG positions).
Real-time quantitative PCR
EFS expression was analyzed by quantitative RT PCR
using UPL-probe No. 17 (Universal probe library,
Roche) and custom-designed primers (EFS-UPLProbe17-
fw: TCCTGAACTGCCCGAGAG; EFS-UPLProbe17-rev:
GCATTGCCCAGCATAGAAGT). We used specific
probes and primers for Human HPRT 1 (hypoxanthine
phosphoribosyltransferase 1) as reference gene (Human
HPRT1 Hs99999909_m1, ABI). An aliquot of 0.5 μg
total RNA was reverse transcribed using the GeneAmp
RNA PCR Kit (ABI) according to the manufacturer’s
instructions. EFS quantitative RT-PCR was carried out
in a volume of 20 μlc o n t a i n i n g1 0μl LightCycler 480
Probes Master, 2 μl of cDNA, 0.3 μM of UPL-probe No.
17 and 1 μM of each primer. Amplification was per-
formed with the Applied Biosystems 7000 Real-Time
PCR System under the following conditions: 95°C for 10
min followed by 40 cycles of denaturation at 95°C for
15 sec and annealing/elongation at 60°C for 1 min. The
mean value of duplicate samples was used for further
analysis. Relative expression levels were calculated by
A
B
C
full methylation
no methylation
partial methylation
Figure 1 Discrimination of methylation states based on direct
bisulfite sequencing chromatograms. Direct sequencing of PCR
products from the EFS CpG island from bisulfite treated DNA. The
reverse sequence is shown here. Therefore, the A signals represent
unmethylated cytosines, which have been converted to thymine
during bisulfite treatment of genomic DNA and the G signals
represent methylated cytosines. (A) The analyzed region was
classified as showing “full methylation” if A-signals were absent at
every CpG; (B) “no methylation” in the absence of G signals at every
CpG position or (C) “partial methylation” if both signals were
present at some or all CpG positions.
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“Guide to Performing Relative Quantitation of Gene
Expression Using Real-Time Quantitative PCR” (Part #:
4371095 Rev B, Applied Biosystems).
Gene dosage analysis of EFS was performed by quanti-
tative PCR using two independent assays located
upstream (GRCh37/Hg19 position: chr14:23,836,138-
23,836,198) and downstream (GRCh37/Hg19 position:
chr14:23,835,737-23,835,837) of the region used for
methylation analysis. UPL-probe No. 55 (Universal
probe library, Roche) was used for measurement of the
PCR product generated with custom-designed primers:
EFS-AMP2-UPLProbe55-fw: GATGTGGGGCTAAT-
GAAAGG and EFS- AMP2-UPLProbe55-rev:
GGTCCGATCGGCTTTCTC. Primers EFS-AMP1-
UPLProbe82-fw: AACTCCTGGTGGGGCTAGAT and
EFS- AMP1-UPLProbe82-rev: GCTGGCACAAAAG
TTGCTAGA were combined with UPL-probes No. 82.
PCR was performed in a volume of 25 μlc o n t a i n i n g
12.5 μl PCR Master Mix without AmpErase (ABI), 15
ng DNA, 0.25 μM of UPL-probe and 0.4 μMo fe a c h
primer. As a reference, we used a region on the proxi-
mal long arm of chromosome 15 (GRCh37/hg19 posi-
tion: chr15:25166001-25166074) [28]. Amplification was
performed with a LightCycler 480 System (Roche) under
the same conditions as described for expression analysis.
All samples were measured in duplicate, and the mean
value was used for further analysis. Relative gene dosage
levels were calculated by the delta-delta-CP method with
the LightCycler 480 software (Roche) using standard
curves and normal control blood DNA for all assays.
Data analysis
Relationship between EFS expression and EFS methyla-
tion was evaluated using pair wise univariate chi-square
test. Kaplan-Meier analysis was calculated using the Sur-
vival/Reliability tool of JMP
® statistical discovery soft-
ware (JMP 7. SAS, Heidenheim, Germany). To
determine the possible correlation of EFS methylation
with clinical variables univariate analysis was performed
using the chi-square test. The Log-Rank test was per-
f o r m e dt ot e s tt h ep r o b a b i l i t yt h a tt h e r ei sat r e n di n
survival scores across two groups in Kaplan-Meier
analysis.
Results
We amplified the EFS CGI on bisulfite-treated DNA
from 16 UMs (set I), cultured uveal tract melanocytes
and 10 blood samples from healthy donors. Methylation
of the CGI was determined by direct sequencing of the
PCR products. This technique provides an average
methylation measurement for each CpG across the
DNA molecules of a given sample. The CGI was classi-
fied either as showing full methylation, no methylation
or partial methylation (Figure 1). We found the EFS
CGI fully methylated in 8 tumors, unmethylated in 5
tumors and partially methylated in 3 tumors. EFS was
also fully methylated in blood DNA from healthy donors
and partially methylated in DNA from cultured melano-
cytes isolated from the uveal tract. Interestingly, EFS
was fully methylated in all but one tumor with monos-
omy 3. In contrast, full methylation was only found in
one of eight tumors with disomy 3 (set I, Table 1).
We analyzed the EFS genome dosage in all 8 tumors
from set I that showed complete EFS methylation by
quantitative RT-PCR to test whether complete methyla-
tion signals might be the result of monoallelic methyla-
tion on the background of a heterozygous EFS deletion.
We found EFS genome dosage normal (two alleles) in
all cases (data not shown), strongly suggesting biallelic
EFS methylation.
Kaplan-Meier analysis was used to compare the out-
come of patients. Survival analysis revealed a reduced
disease free survival of patients with complete or partial
EFS methylation in their tumor (p = 0.02; Figure 2).
However, as the number of patients in set I was rather
small, we analyzed another set of 24 tumors randomly
chosen from a cohort of 246 tumor samples showing
either monosomy 3 or disomy 3. In this confirmatory
group (set II), the significant correlation of EFS methyla-
tion and metastatic death of patients was confirmed (p =
0.02). Notably, only tumors with EFS methylation gave
rise to metastases. The correlation is more significant
when combined analysis of tumors from set I and set II
(40 tumors) is performed (p = 0.001) and when tumors
showing partial methylation are analyzed as separate
group (p = 0.0004) (Figure 2).
Univariate analyses by pair wise comparison of EFS
methylation with the variables listed in table 1 revealed
a highly significant correlation of the EFS methylation
with the chromosome 3 status (p = 1.6 × 10
-6) and cell
type (p = 0.006). For the continuous parameters of
tumors such as LBD (largest basal diameter), SBD
(smallest basal diameter), prominence and patients’ age
at diagnosis we used a logistic model and found that
LBD and age at diagnosis reached significance with p =
0.03 and p = 0.02, respectively.
We evaluated the possible correlation of EFS methyla-
tion and EFS expression by performing real-time quanti-
tative RT-PCR on mRNA from the same set of tumors
used for initial methylation analysis (set I; Figure 3). EFS
expression was strongly reduced in tumors that showed
complete EFS methylation compared to unmethylated
tumor samples (p = 0.008).
To address the possibility of tissue-specific EFS
methylation indicated by the distinct methylation in
blood cells and melanocytes we performed methylation
analysis of various normal tissue samples and primary
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Page 4 of 11Table 1 Clinical data of the patients included in the study
Tumors Patients
tumor
ID
prominence
[mm]
LBD
[mm]
SBD
[mm]
cell
type
ciliary body
involvement
chr.3
status
chr.8
alteration
EFS
methylation
patient
ID
age at diagnosis
[years]
sex survival metastatic
death
follow up time
[months]
set
I
T1 5.9 11.9 11.7 sc no D3 AI no 28914 69 m alive - 51
T2 5.8 11.2 10.6 sc no D3 AI no 28101 69 f alive - 57
T3 14.0 19.0 n.d. sc no D3 AI no 25722 48 f alive - 67
T4 9.2 20.9 20.8 ec no D3 AI partial 29311 39 m deceased yes 18
T5 11.4 19.0 11.9 sc no D3 no full 29802 66 f alive - 47
T6 15.6 15.3 14.5 sc no D3 AI no 22978 50 f alive - 81
T7 9.2 10.0 8.7 sc no D3 AI no 29101 64 f alive - 52
T8 11.7 13.5 12.2 sc no D3 AI partial 29380 72 m alive - 51
T9 10.8 n.d. n.d. sc no M3 AI full 30545 65 m alive - 46
T10 12.0 13.4 11.9 sc no M3 no partial 27745 67 f deceased no 45
T11 10.3 21.9 21.1 mc yes M3 AI full 24905 66 m deceased yes 26
T12 9.8 17.0 13.5 mc no M3 AI full 24903 64 f deceased yes 43
T13 10.6 21.3 17.4 mc no M3 AI full 25726 57 m deceased yes 19
T14 9.8 25.0 21.0 sc yes M3 AI full 24464 62 m deceased yes 22
T15 11.3 15.5 11.6 sc yes M3 AI full 27587 61 f deceased yes 20
T16 8.5 n.d. n.d. sc yes M3 AI full 25243 62 m deceased yes 18
set
II
T17 7.1 11.2 10.6 sc yes D3 AI no 14514 58 f alive - 125
T18 9.9 16.0 11.9 sc yes D3 AI no 17003 55 m alive - 112
T19 10.4 15.5 14.4 sc no D3 AI no 17453 19 f alive - 110
T20 9.8 16.1 14.5 sc yes D3 AI no 18671 46 f alive - 104
T21 8.4 8.8 8.7 mc no D3 no partial 19207 69 m alive - 102
T22 n.d. 9.4 8.6 sc no D3 no no 21436 38 m alive - 89
T23 10.7 17.2 14.5 sc no D3 no no 31091 63 m alive - 44
T24 16.2 21.3 17.2 sc no D3 AI no 31412 45 m alive - 39
T25 6.0 13.4 12.1 sc n.d. D3 n.d. no 33708 68 m alive - 29
T26 12.5 12.1 9.8 sc no D3 no no 36500 73 f alive - 20
T27 12.0 22.7 18.9 sc no M3 AI partial 17451 68 m deceased no 37
T28 10.5 24.3 19.6 mc yes M3 no full 18465 77 m deceased yes 37
T29 12.3 16.0 15.2 mc no M3 AI full 20012 76 m deceased yes 6
T30 10.7 17.7 16.6 mc yes M3 AI full 21501 71 m deceased yes 46
T31 11.3 n.d. n.d. mc yes M3 AI full 22095 74 m deceased yes 2
T32 11.9 16.9 15.4 sc no M3 AI full 22543 69 m deceased yes 5
T33 9.3 20.0 n.d. mc no M3 no full 22805 70 m deceased no 18
T34 10.6 15.8 15.5 sc yes M3 AI full 25720 61 m deceased yes 50
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1Table 1 Clinical data of the patients included in the study (Continued)
T35 13.7 n.d. n.d. sc no M3 AI partial 26072 76 m alive - 61
T36 11.3 11.4 7.0 mc yes M3 AI full 27766 63 m deceased yes 35
T37 10.1 12.9 10.7 sc yes M3 AI full 29132 69 f alive - 52
T38 10.1 20.4 16.5 sc nd M3 no full 29337 74 f alive - 51
T39 13.6 18.0 14.5 mc no M3 AI full 32516 50 f deceased yes 30
T40 8.3 12.5 11.5 mc no M3 AI full 34922 54 f alive - 24
Methylation status of EFS as determined by direct sequencing of PCR products from bisulfite treated DNA; LBD, largest tumor diameter; SBD, smallest tumor diameter; M3, monosomy 3; D3, normal (retention of both
alleles) chromosome 3 status; AI, allelic imbalance; m, male; f, female; sc, spindle cell; mc, mixed cell; ec, epitheloid cell type; n.d., not determined.
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1cells (Table 2). EFS was unmethylated in all sperm sam-
ples, most fetal tissues, cultured primary fibroblasts and
one of four buccal swab samples. Complete methylation
w a so b s e r v e di n1 3o f1 5b l o o ds a m p l e sf r o mU M
patients. Two blood samples from UM patients (PUM1
and PUM15), three buccal swab samples from normal
donors and all adult brain samples showed the presence
of methylated and unmethylated signals at all CpG dinu-
cleotides, and thus, were classified as partially
methylated.
To evaluate the nature of partial methylation in more
detail we cloned PCR products from representative sam-
ples with partial EFS methylation and sequenced indivi-
dual clones (Figure 4). Cloned PCR products represent
the methylation pattern of a single allele and might
facilitate discrimination between allele-specific methyla-
tion and incomplete methylation of both alleles. We
chose samples informative for a polymorphism in the
analyzed region (SNP rs3759609), which allows for allele
discrimination. In one buccal swab sample, both alleles
were found either methylated or unmethylated
suggesting the presence of a mixture of methylated and
unmethylated cells. Incomplete, but biallelic methylation
was found in UM sample T10. In cultured melanocytes,
EFS methylation was less dense, but still affected both
alleles. Allele-specific EFS methylation was found in
none of the samples.
Discussion
We found the methylation of the CGI located in the
promoter region of EFS to be biallelic in all nine UM
samples analyzed in this respect (eight fully methylated
and one partially methylated UM from set I). Such fre-
quent biallelic methylation is unlikely to occur through
random epimutations and suggests the action of a site-
directed de novo methylation mechanism, which is dis-
tinct from the two-step mutation-selection process that
underlies allele-specific de novo hypermethylation of
tumor suppressor genes. Tissue-specific methylation of
EFS with full methylation in blood cells and partial or
no methylation in most other tissues further argues for
the involvement of such a methylation mechanism in
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Figure 2 Kaplan-Meier curves showing disease-specific mortality of UM patients. Patients are grouped according to the EFS methylation
status in their tumor. Partially and fully methylated samples are grouped together (A, B and C). (A) Set I: 16 patients used for the initial EFS CGI
methylation analysis (p = 0.02). (B) Set II; confirmatory cohort of 24 randomly chosen tumor samples (p = 0.02). (C) Combined analysis of all 40
samples (setI + set II). (D) Combined analysis of all 40 samples (setI + set II) with partially methylated samples as separate group.
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Page 7 of 11the differentiation of the hematopoietic cell lineage. Site-
specific methylation mechanisms, which may require the
interaction of cis- and trans-acting factors, have been
reported to be responsible for de novo methylation of
tissue-specific methylated genes such as the POU5F1
pluripotency factor and are major components of cellu-
lar differentiation [12]. Most of the molecular compo-
nents controlling this process are not yet known. With
respect to UM, it would be interesting to find out if
other genes are targeted by the same de novo methyla-
tion mechanism responsible for EFS methylation. Identi-
fication of these genes might provide further insight
into the biological difference inherent to both uveal
melanoma classes as methylation is strongly associated
with metastatic progression.
The strong correlation of EFS methylation with tran-
scriptional EFS silencing observed in UM shows that
EFS is subjected to long term inactivation by the methy-
lation mechanism. The EFS promoter might therefore
belong to the group of tissue-specific differentially
methylated regions that contribute to tissue-specific
transcription control [29].
We detected partial methylation in DNA from some
normal tissue samples. Tissue heterogeneity might con-
tribute to this observation as blood cells, which are
methylated at EFS, are likely to contribute to the DNA
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unmethylated and fully methylated tumor samples was statistically significant with p = 0.008 (Chi square). Differences between unmethylated
and partially methylated tumors as well as between partially methylated and fully methylated tumors were not statistically significant.
Neumann et al. BMC Cancer 2011, 11:380
http://www.biomedcentral.com/1471-2407/11/380
Page 8 of 11extracted from some tissue samples. Partial methylation
was also found in cultured uveal melanocytes. As these
cells were grown in geneticin at a concentration toxic
for non-melanocytic cells, methylated EFS alleles are
likely to be derived from melanocytes [22]. We cannot
exclude that EFS methylation in these cells may have
arisen in the course of cultivation. However, no EFS
methylation was detected in cultured primary fibroblasts
indicating that growing primary cells under cell culture
conditions per se is not sufficient to induce EFS methy-
lation. Analysis of individual clones representing indivi-
dual alleles revealed CGI methylation of both parental
EFS alleles (A and G allele; Figure 4B.), which argues for
the existence of both methylated and unmethylated mel-
anocytes in the uveal tract.
Genome and transcriptome analyses have shown that
UMs fall into two classes that are congruent with high
and low risk of death from metastatic disease [1,2]. Here
we found that EFS methylation is significantly correlated
with patients’ survival and the chromosome 3 status of
the tumors. In fact, all patients in our series who died of
metastases showed EFS methylation in their primary
tumors. Correlation of EFS methylation, although to a
lesser extent, was also observed with the cell type, age at
diagnosis and LBD. These parameters have previously
been shown to correlate with monosomy 3 in UM sug-
gesting that EFS methylation is a typical feature of the
tumor class characterized by monosomy 3.
From our data we cannot decide if the EFS methyla-
tion state was already present in tumor precursors or if
it was acquired during tumorigenesis. Taking the differ-
entially methylated melanocyte precursors into account,
we propose that tumors with EFS methylation might be
direct descendants from methylated precursors. Further
progression of these tumors into a highly malignant
tumor phenotype might frequently, but not necessarily,
be accompanied by loss of a chromosome 3. This is in
agreement with the idea of different melanocytic precur-
sors as origin of the different classes of UM previously
published by Tschentscher et al. and Chang et al. [2,6]
Table 2 EFS methylation in different tissues and cell
types
Tissue/
cell type
Number of
samples
Methylation
full partial no
Blood 10 10 0 0
Blood (patients) 15 13 2 0
Melanocytes 3 0 3 0
Fibroblasts 4 0 0 4
Sperm 2 0 0 2
Buccal swab 4 0 3 1
Brain (adult) 4 0 4 0
Brain (fetal) 1 0 0 1
Kidney (fetal) 1 0 0 1
Muscle (fetal) 1 0 0 1
Liver (fetal) 1 0 1 0
Figure 4 EFS CpG island analysis showing tissue-specific
degrees of methylation. (A) Map of the EFS promoter and exon1/
exon2 region. CGI 131 (GRCh37/Hg19, black bar), which
encompasses 144 CpG positions, overlaps with the EFS transcription
start site (TSS). The analyzed region covers 260 bases of the CGI
containing 27 CpG dinucleotides and is located upstream of the EFS
TSS. The first analyzed CpG position is not part of the CGI (GRCh37/
hg19). (B) Detailed methylation analysis of samples showing partial
EFS methylation as determined by sequence analysis of cloned PCR
products from one buccal swab sample, cultured uveal melanocytes
and UM sample T10. Each row of boxes represents the CpGs of an
individual PCR product. Each column represents a specific CpG in
the analyzed region. Allelic discrimination was facilitated by an
informative SNP (rs3759609). White boxes, unmethylated CpGs; black
boxes, methylated CpGs; n.d., methylation state was not
determined.
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Page 9 of 11Although EFS has been recognized as a member of the
CAS protein family, little is known about its function so
far. The protein contains a Src homology 3 (SH3)
domain and has first been identified by interactions with
the Src-family kinases Src, Fyn and Yes in mice [30,31].
Like other CAS family members EFS seems to act as an
adapter protein, which is regulated by phosphorylation
but has no enzymatic activities [32]. It was shown to be
expressed in the thymic stroma [33] where it is involved
in T-lymphocyte regulation and EFS-knockout mice
develop exaggerated T-cell responses and inflammatory
lesions [34]. EFS has not been linked to cancer, so far.
However, other members of the CAS family can act as
oncogenes and have been linked to metastasis and poor
prognosis [32]. Involvement of the CAS proteins BCAR1
and NEDD9 in focal adhesions and mitotic spindle
assembly, respectively, might hint towards implications
of EFS in UM invasion or chromosome 3 loss.
Conclusions
Biallelic EFS methylation hints towards a site-specific
methylation mechanism. Partial, but biallelic methylation
in cultured melanocytes from the uveal tract suggests
that there are methylated and unmethylated precursor
cells. Therefore, EFS methylation of an UM may depend
on which type of precursor cell the tumor originated
from. It remains to be elucidated whether biallelic EFS
methylation is established during progression of UM, or
whether it mainly represents an early epigenetic flag
that traces the two tumor classes back to their precursor
cell. Identifying other genes targeted by the site-specific
methylation mechanism might provide further insight
into the biological difference underlying both UM
classes.
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